多发性内分泌腺瘤病1型患者原发甲状旁腺功能亢进症:基因型与手术方式对长期术后结局的影响
研究纳入1985至2020年本机构评估的209例多发性内分泌腺瘤病1型(MEN1)患者,其中194例(93%)诊断原发甲状旁腺功能亢进症,按基因型与首次手术方式分层。截短变异位于外显子2、9或10者较其他变异者诊断年龄更小(27岁 vs 31岁;P = .006)。首次手术为小于次全甲状旁腺切除术(<SPTX)者无病生存期显著差于次全甲状旁腺切除术(SPTX)(60个月 vs 152个月;P = .0005)或全甲状旁腺切除术(210个月;P = .04);截短变异者行<SPTX的无病生存期亦显著短于其他变异者(30个月 vs 84个月;P = .007)。最终手术后持续性甲状旁腺功能减退发生率以全甲状旁腺切除术最高(40%),<SPTX为9%,SPTX为7%。
要点
- MEN1相关原发甲状旁腺功能亢进症中,外显子2、9或10截短变异者诊断年龄更小(27岁 vs 31岁;P = .006)。
- 首次手术为<SPTX者无病生存期显著差于SPTX(60个月 vs 152个月;P = .0005)和全甲状旁腺切除术(210个月;P = .04)。
- 截短变异者行<SPTX的无病生存期显著短于其他变异者(30个月 vs 84个月;P = .007)。
核心结论
- MEN1基因型可能影响原发甲状旁腺功能亢进症的发病年龄及术后复发时间。
- 首次手术采用<SPTX应谨慎,尤其对于MEN1外显子2、9或10截短变异患者,其较高的复发风险并未被永久性甲状旁腺功能减退发生率的降低所抵消(与 upfront SPTX 相比)。
研究设计与样本
- 研究识别1985年至2020年在本机构评估的MEN1患者,按基因型(外显子2、9或10截短变异或其他变异)和首次手术方式(小于次全甲状旁腺切除术[<SPTX]、次全甲状旁腺切除术[SPTX]或全甲状旁腺切除术)分层。
- 共识别209例患者,其中194例(93%)诊断原发甲状旁腺功能亢进症。
主要发现
- 外显子2、9或10截短变异者诊断原发甲状旁腺功能亢进症的中位年龄为27岁,其他变异者为31岁(P = .006)。
- 首次手术为<SPTX者的中位无病生存期为60个月,SPTX者为152个月(P = .0005),全甲状旁腺切除术者为210个月(P = .04)。
- 外显子2、9或10截短变异者行<SPTX的中位无病生存期为30个月,其他变异者为84个月(P = .007)。
- 最终手术后持续性甲状旁腺功能减退发生率:全甲状旁腺切除术40%,<SPTX 9%,SPTX 7%。
临床怎么用
- 作者认为首次手术采用<SPTX应谨慎,尤其对于MEN1外显子2、9或10截短变异患者,其较高的复发风险并未被永久性甲状旁腺功能减退发生率的降低所抵消(与 upfront SPTX 相比)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Protein-truncating germline pathogenic variants in the N- and C-terminal exons (2, 9, and 10) of the MEN1 gene may be associated with aggressive pancreatic neuroendocrine tumors. However, the impact of these variants on parathyroid disease is poorly understood. We sought to investigate the effects of genotype and surgical approach on clinical phenotype and postoperative outcomes in patients with multiple endocrine neoplasia type 1 (MEN1)-related primary hyperparathyroidism. METHODS: We identified patients with MEN1 evaluated at our institution from 1985 to 2020 and stratified them by genotype, (truncating variants in exons 2, 9, or 10, or other variants), and index surgical approach, (less-than-subtotal parathyroidectomy [<SPTX], SPTX, or total parathyroidectomy). We analyzed baseline characteristics, persistent/recurrent disease rates, and incidence of postoperative hypoparathyroidism. RESULTS: Of the 209 patients we identified, primary hyperparathyroidism was diagnosed in 194 (93%) and at a younger median age in those with truncating exon 2, 9, or 10 variants compared with other variants (27 years vs 31 years; P = .006). Median disease-free survival was significantly worse in patients who underwent <SPTX (60 months) than those who underwent <SPTX (152 months; P = .0005) or total parathyroidectomy (210 months; P = .04). Patients with truncating exon 2, 9, or 10 variants who underwent <SPTX had significantly shorter median disease-free survival than those with other variants (30 vs 84 months; P = .007). Prolonged hypoparathyroidism rates after final surgery were highest after total parathyroidectomy (40%), followed by <SPTX (9%) and SPTX (7%). CONCLUSION: The MEN1 genotype may affect the age of onset of primary hyperparathyroidism and the time to recurrence after surgery. <SPTX at index operation should be performed with caution, especially in patients with truncating MEN1 variants in exons 2, 9, or 10, as the higher risk of recurrence is not offset by a decreased incidence of permanent hypoparathyroidism compared to upfront SPTX.
引用
- Shariq OA, Abrantes VB, Lu LY, et al. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: Impact of genotype and surgical approach on long-term postoperative outcomes. Surgery. 2023. PMID: 37891063. doi:10.1016/j.surg.2023.05.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。